RSS Feed ALL

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

about 7 hours ago

Follows Favorable Multi-District Litigation Court Causation Ruling and the Company’s Successful Strategy...

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

5 days ago

· Investigational MonumenTAL-6 trial is the first and only Phase 3 study...

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

6 days ago

DePuy Synthes Acquires Expanding Innovations™

12 days ago

Transaction will bring expandable interbody cage solutions to DePuy Synthes' Spine portfolio...

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

12 days ago

● New branded recognition will spotlight the care, innovation and grit of...

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

13 days ago

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

13 days ago

2025 Second-Quarter reported sales growth of 5.8% to $23.7 Billion with operational...

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

20 days ago

· Dual Energy THERMOCOOL SMARTTOUCH SF Platform brings pulse field and radiofrequency...

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

20 days ago

· Dual Energy THERMOCOOL SMARTTOUCH SF Platform brings pulse field and radiofrequency...

DePuy Synthes Appoints Christina Zamarro as Chief Financial Officer

28 days ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

about 1 month ago

· New analyses from the Phase 3 Vivacity-MG3 study support the impact...

CHMP recommendation advances Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab as a potential standard of care for relapsed/refractory multiple myeloma

about 1 month ago

Recommendation supported by unprecedented Phase 3 data, demonstrating that TECVAYLI® in combination...